FrancophonIA/ELRC3.0 huggingface dataset:
English: Myocet liposomal 50 mg concentrate for dispersion for infusion Liposomal doxorubicin HCl
Slovenian: Myocet liposomal 50 mg koncentrat till infusionsvätska, dispersion liposomal doxorubicin HCl i.v.
English: Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion Liposomal doxorubicin hydrochloride
Slovenian: Myocet liposomal 50 mg pulver, dispersion och vätska till koncentrat till infusionsvätska, dispersion liposomal doxorubicinhydroklorid
English: Increased serum bilirubin
Slovenian: Förhöjt bilirubin i serum Mindre vanliga
English: MARKETING AUTHORISATION NUMBER(S)
Slovenian: NUMMER PÅ GODKÄNNANDE FÖR FÖRSÄLJNING
English: 6.3 Shelf life
Slovenian: 6.3 Hållbarhet
English: Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion.
Slovenian: Myocet liposomal 50 mg pulver, dispersion och vätska till koncentrat till infusionsvätska, dispersion.
English: Package leaflet: Information for the user Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion
Slovenian: Bipacksedel: Information till användaren Myocet liposomal 50 mg pulver, dispersion och vätska till koncentrat till infusionsvätska, dispersion liposomal doxorubicinhydroklorid
English: What Myocet liposomal looks like and contents of the pack
Slovenian: Hur Myocet liposomal ska förvaras Förpackningens innehåll och övriga upplysningar
English: Vial 1 - doxorubicin HCl lactose
Slovenian: Injektionsflaska 1 - doxorubicin HCl laktos
English: Musculoskeletal, connective tissue and bone disorders
Slovenian: Muskuloskeletala systemet och bindväv
English: Lymphopenia
Slovenian: Lymfopeni
English: ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Slovenian: BILAGA I PRODUKTRESUMÉ
English: Bilirubin > ULN but < 50 μmol/l
Slovenian: överväg 25 % dosreduktion bilirubin > övre normalvärde men < 50 µmol/l
English: Excipients:
Slovenian: Hjälpämnen:
English: Headache
Slovenian: Smärta
English: How Myocet liposomalis given
Slovenian: Hur Myocet liposomal ska förvaras
English: Myocet liposomal contains sodium
Slovenian: Myocet innehåller natrium
English: οC.
Slovenian: Utg.dat.
English: Arrhythmia
Slovenian: Hemoptys
English: MARKETING AUTHORISATION HOLDER
Slovenian: INNEHAVARE AV GODKÄNNANDE FÖR FÖRSÄLJNING
English: Vial 1 - doxorubicin HCl is a red lyophilised powder.
Slovenian: Myocet liposomal levereras som ett system av tre injektionsflaskor enligt följande: Injektionsflaska 1 - doxorubicin HCl är ett rött frystorkat pulver.
English: Injection site reactions
Slovenian: Reaktioner vid injektionsstället
English: What is in this leaflet:
Slovenian: I denna bipacksedel finns information om följande:
English: Increased hepatic transaminases
Slovenian: Förhöjda levertransaminaser
English: Analyses of cardiotoxicity in clinical trials have shown a statistically significant reduction in cardiac events in patients treated with Myocet liposomal compared to patients treated with conventional doxorubicin at the same dose in mg. A meta-analysis showed a statistically significant lower rate of both clinical heart failure (RR = 0.20, p=0.02) and clinical and subclinical heart failure combined (RR = 0.38, p<0.0001) in patients treated with Myocet liposomal versus conventional doxorubicin.
Slovenian: En metaanalys visade statistiskt signifikant lägre frekvens av både klinisk hjärtsvikt (RR=0,20, p= 0,02) och kombinerad klinisk och subklinisk hjärtsvikt (RR=0, 38, p<0,0001) hos patienter som behandlats med Myocet liposomal jämfört med konventionellt doxorubicin.
English: • muscle weakness
Slovenian: • muskelvärk, ryggont
English: Pregnancy and breast-feeding
Slovenian: Graviditet och amning
English: • hair loss
Slovenian: • huvudvärk
English: Not known
Slovenian: Ingen känd frekvens
English: Radiation therapy
Slovenian: Behandling med strålning
English: EXPIRY DATE
Slovenian: UTGÅNGSDATUM
English: Posology
Slovenian: Ryggsmärtor
English: Dox 60/CPA mg/m2) (n=155)
Slovenian: mg/m2) (n=155)
English: SHAKE
Slovenian: Faryngit
English: Dizziness
Slovenian: Stelhet
English: Malaise
Slovenian: Mukosit
English: Median PFS (months)a
Slovenian: Median-PFS (månader)a Riskförhållande (95% C.I.)
English: Jaundice
Slovenian: Hjärtat
English: Pleural effusion
Slovenian: Stomatit/mukosit
English: Instructions for use: a) Prepare a dose
Slovenian: Navodila za uporabo: a) Pripravite odmerek
English: Hold this breath in for as long as possible (at least 3-4 seconds).
Slovenian: Zadržite ta dih, kolikor je mogoče dolgo (vsaj 3 do 4 sekunde).
English: Date of latest renewal: 11 January 2019
Slovenian: Datum prve odobritve: 28. april 2014 Datum zadnjega podaljšanja: 11. januar 2019
English: It is very important that you use Incruse Ellipta every day, as instructed by your doctor.
Slovenian: Zelo pomembno je, da zdravilo Incruse Ellipta uporabljate vsak dan, kot vam je naročil zdravnik.
English: Umeclidinium bromide should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the foetus.
Slovenian: Umeklidinijev bromid se sme med nosečnostjo uporabljati le, če je pričakovana korist za mater večja od možnega tveganja za plod.
English: The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data).
Slovenian: Pogostnost neželenih učinkov je opredeljena z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
English: The first time you use Incruse Ellipta you do not need to check that the inhaler is working properly; it contains previously measured doses and is ready to use straight away.
Slovenian: Ko zdravilo Incruse Ellipta prvič uporabite, vam ni treba preverjati, ali inhalator deluje pravilno; inhalator vsebuje predhodno odmerjene odmerke in je pripravljen za takojšnjo uporabo.
English: if you are allergic to umeclidinium or any of the other ingredients of this medicine (listed in section 6).
Slovenian: - če ste alergični na umeklidinij ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Umeclidinium bromide has no or negligible influence on the ability to drive and use machines.
Slovenian: Umeklidinijev bromid nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
English: After this date the inhaler should no longer be used.
Slovenian: Po tem datumu se inhalatorja ne sme več uporabljati.
English: A decision must be made whether to discontinue breast-feeding or to discontinue Incruse Ellipta therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Slovenian: Odločiti se je treba bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja z zdravilom Incruse Ellipta, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko.
English: Don't inhale an extra dose to make up for a forgotten dose.
Slovenian: Ne vdihnite dodatnega odmerka, da bi nadomestili pozabljenega.
English: Incruse Ellipta should be administered at the same time of the day each day to maintain bronchodilation.
Slovenian: Zdravilo Incruse Ellipta je treba uporabljati vsak dan ob istem času, za ohranjanje bronhodilatacije.
English: Do not use this medicine after the expiry date which is stated on the carton, tray and inhaler after ‘EXP'.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatlah, embalaži ali inhalatorju poleg oznake ‘EXP'.
English: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not use this medicinal product.
Slovenian: Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo uporabljati tega zdravila.
English: Toxicity to reproduction
Slovenian: Reprodukcijska toksičnost
English: Not all pack sizes may be marketed.
Slovenian: Na trgu morda ni vseh velikosti pakiranj.
English: Don't use Incruse Ellipta as well as these other medicines.
Slovenian: Ne uporabljajte zdravila Incruse Ellipta hkrati s temi drugimi zdravili.
English: The short duration of these two studies and limited number of exacerbation events, preclude any conclusion regarding additional effect of Incruse Ellipta on COPD exacerbation rate.
Slovenian: Kratkotrajnost teh dveh študij in majhno število poslabšanj onemogočajo sklepanje o dodatnem učinku zdravila Incruse Ellipta na delež poslabšanj KOPB.
English: 1) Read this before you start
Slovenian: 1) Pred začetkom uporabe preberite navodila.
English: These may affect up to 1 in 1,000 people:
Slovenian: Pojavijo se lahko pri največ 1 od 1.000 bolnikov:
English: The tray can be discarded after first opening.
Slovenian: Embalažo se lahko po prvem odprtju zavrže.
English: The other ingredients are lactose monohydrate (see section 2 under ‘Incruse Ellipta contains lactose') and magnesium stearate.
Slovenian: Drugi sestavini zdravila sta laktoza monohidrat (glejte poglavje 2 "Zdravilo Incruse Ellipta vsebuje laktozo") in magnezijev stearat.
English: The absolute bioavailability of inhaled umeclidinium bromide was on average 13% of the dose, with negligible contribution from oral absorption.
Slovenian: Absolutna biološka uporabnost inhaliranega umeklidinijevega bromida je bila v povprečju 13 % odmerka; prispevek peroralne absorpcije je bil zanemarljiv.
English: • Remove the inhaler from the mouth.
Slovenian: • Vzemite inhalator iz ust.
English: Patients receiving Incruse Ellipta had a higher percentage of days when no rescue medication was needed (on average 31.1%) compared with placebo (on average 21.7%).
Slovenian: Bolniki, ki so dobivali zdravilo Incruse Ellipta so imeli večji odstotek dni brez potrebe po rešilnem zdravilu (povprečno 31,1 %) v primerjavi s placebom (povprečno 21,7 %).
English: The primary endpoint was annual rate of ontreatment moderate and severe exacerbations in subjects treated with FF/UMC/VI compared with FF/VI.
Slovenian: Primarni opazovani dogodek je bil letni delež zmernih in hudih poslabšanj med zdravljenjem pri bolnikih, zdravljenih s FF/UMC/VI v primerjavi s FF/VI.
English: If you have any of the following symptoms after taking Incruse Ellipta, stop using this medicine and tell your doctor immediately:
Slovenian: Če imate po jemanju zdravila Incruse Ellipta katerega koli od naslednjih simptomov, zdravilo takoj nehajte uporabljati in nemudoma obvestite svojega zdravnika:
English: 2) Prepare a dose
Slovenian: 2) Priprava odmerka
English: It is not known whether the ingredients of Incruse Ellipta can pass into breast milk.
Slovenian: Ni znano, ali lahko sestavine zdravila Incruse Ellipta prehajajo v materino mleko.
English: No dose adjustment is required in patients over 65 years (see section 5.2).
Slovenian: Starejši bolniki Bolnikom, starejšim od 65 let, odmerka ni treba prilagoditi (glejte poglavje 5.2).
English: Incruse Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Slovenian: Zdravilo Incruse Ellipta je indicirano za vzdrževalno bronhodilatacijsko zdravljenje za olajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
English: Component of a multipack, can't be sold separately.
Slovenian: Del pakiranja z več inhalatorji, ni za ločeno prodajo.
English: Allergic reactions are uncommon (may affect up to 1 in 100 people).
Slovenian: Alergijske reakcije pri zdravilu Incruse Ellipta so občasne (pojavijo se lahko pri največ 1 od 100 bolnikov).
English: How to use the inhaler See ‘Step-by-step instructions for use' in this leaflet for full information.
Slovenian: Za celotne informacije glejte "Navodila za uporabo po korakih" v tem navodilu.
English: If you open and close the cover without inhaling the medicine, you will lose the dose.
Slovenian: Če pokrovček odprete in zaprete, ne da bi vdihnili zdravilo, boste izgubili odmerek.
English: Incruse Ellipta contains the active substance umeclidinium bromide, which belongs to a group of medicines called bronchodilators.
Slovenian: Zdravilo Incruse Ellipta vsebuje učinkovino umeklidinijev bromid, ki spada v skupino zdravil, imenovanih bronhodilatatorji.
English: Submission of the final clinical study report on a Post-Authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients with Incruse Ellipta compared with tiotropium (study 201038), according to a protocol agreed by the PRAC.
Slovenian: Opazovalna kohortna študija za določitev incidence in primerjalne varnosti za izbrane kardiovaskularne in cerebrovaskularne dogodke pri bolnikih s KOPB z zdravilom Incruse Ellipta v primerjavi s tiotropijem (študija 201038), po porotokolu, ki ga je potrdil PRAC.
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.
Slovenian: • Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive
English: What you need to know before you use Incruse Ellipta 3.
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Incruse Ellipta 3.
English: The bronchodilatory effects with Incruse Ellipta compared with placebo were evident after the first day of treatment in both studies and were maintained over the 12-week and 24-week treatment periods.
Slovenian: V obeh študijah so bili bronhodilatacijski učinki zdravila Incruse Ellipta v primerjavi s placebom opazni že po prvem dnevu zdravljenja in so se ohranili med 12- in 24-tedenskim obdobjem zdravljenja.
English: Driving and using machines It is unlikely that this medicine will affect your ability to drive or use machines.
Slovenian: Ni verjetno, da bi to zdravilo vplivalo na vašo sposobnost upravljanja vozil in strojev.
English: There was no evidence for tachyphylaxis in the effect of Incruse Ellipta over time.
Slovenian: Ni bilo znakov, da bi se skozi čas razvila tahifilaksija na učinek zdravila Incruse Ellipta.
English: Incruse Ellipta has not been studied in patients with severe hepatic impairment and should be used with caution (see section 5.2).
Slovenian: Uporaba zdravila Incruse Ellipta ni raziskana pri bolnikih s hudo okvaro jeter, zato ga je pri takšnih bolnikih treba uporabljati previdno (glejte poglavje 5.2).
English: Table 1: Trough FEV1 (ml) at Week 12 and Week 24 (primary endpoint) Treatment with Incruse Ellipta 55 mcg
Slovenian: Preglednica 1: Najnižji FEV1 (ml) 12. in 24. teden (primarni opazovani dogodek) Zdravljenje z zdravilom Incruse Ellipta 55 µg
English: It is not possible to accidentally take extra medicinal product or a double dose in one inhalation.
Slovenian: Ne more se zgoditi, da bi pri eni inhalaciji pomotoma vzeli dodatno količino zdravila ali dvojen odmerek.
English: The mouthpiece should be placed between the lips and the lips should then be closed firmly around it.
Slovenian: Ustnik namestite med ustnici in ju trdno stisnite okrog njega.
English: LIST OF EXCIPIENTS Excipients: lactose and magnesium stearate.
Slovenian: Pomožne snovi: laktoza in magnezijev stearat.
English: Each delivered dose contains approximately 12.5 mg of lactose (as monohydrate).
Slovenian: Pomožna snov z znanim učinkom: En oddani odmerek vsebuje približno 12,5 mg laktoze (v obliki laktoze monohidrata).
English: The effect of umeclidinium 500 micrograms (pre-dispensed) on the QT interval was evaluated in a placebo- and moxifloxacin-controlled QT trial of 103 healthy volunteers.
Slovenian: Vpliv 500 mikrogramov umeklidinija (odmerjeni) na interval QT so ocenili pri 103 zdravih prostovoljcih v študiji QT, kontrolirani s placebom in moksifloksacinom.
English: In a pre- and post-natal study, subcutaneous administration of umeclidinium bromide to rats resulted in lower maternal body weight gain and food consumption and slightly decreased pre-weaning pup body weights in dams given 180 micrograms/kg/day dose (approximately 80-times the human clinical exposure of umeclidinium 55 micrograms, based on AUC).
Slovenian: V pre- in postnatalni študiji je subkutano dajanje umeklidinijevega bromida pri podganah zmanjšalo materino povečanje telesne mase in uživanje hrane ter rahlo zmanjšalo telesno maso mladičev pred odstavitvijo pri samicah-materah, ki so dobivale odmerek 180 mikrogramov/kg/dan (to je na podlagi AUC približno 80-kratnik klinične izpostavljenosti pri človeku z odmerkom 55 mikrogramov umeklidinija).
English: Stop using this medicine and seek medical help immediately, these may be signs of an acute attack of narrow-angle glaucoma.
Slovenian: Prenehajte uporabljati to zdravilo in nemudoma poiščite zdravniško pomoč; to so lahko znaki akutnega napada glavkoma z ozkim zakotjem.
English: What you need to know before you use Incruse Ellipta Do not use Incruse Ellipta:
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Incruse Ellipta Ne uporabljajte zdravila Incruse Ellipta:
English: It is not possible to accidentally take extra medicine or a double dose in one inhalation.
Slovenian: Ne more se zgoditi, da bi pri eni inhalaciji pomotoma vzeli dodatno količino zdravila ali dvojni odmerek.
English: If the inhaler cover is opened and closed without inhaling the medicinal product, the dose will be lost.
Slovenian: Če se pokrovček inhalatorja odpre in zapre, ne da bi se zdravilo vdihnilo, bo odmerek izgubljen.
English: The clinical efficacy of Incruse Ellipta administered once daily was evaluated in 904 adult patients who received umeclidinium bromide or placebo from two pivotal Phase III clinical studies with a clinical diagnosis of COPD; a 12-week study (AC4115408) and a 24-week study (DB2113373).
Slovenian: Klinično učinkovitost zdravila Incruse Ellipta enkrat na dan so ocenili pri 904 odraslih bolnikih s klinično diagnozo KOPB, ki so prejemali umeklidinijev bromid ali placebo v dveh ključnih kliničnih študijah III. faze: v 12-tedenski študiji (AC4115408) in 24-tedenski študiji (DB2113373).
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland GlaxoSmithKline (Ireland) Limited logo
Slovenian: GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska GlaxoSmithKline (Ireland) Limited logo
English: • While holding the inhaler away from your mouth, breathe out as far as is comfortable.
Slovenian: • Medtem ko inhalator držite odmaknjen od ust, izdihnite čim bolj globoko, a ne toliko, da bi bilo neprijetno.
English: The most frequently reported adverse reactions with Incruse Ellipta were nasopharyngitis and upper respiratory tract infection.
Slovenian: Najpogosteje poročana neželena učinka med uporabo zdravila Incruse Ellipta sta bila nazofaringitis in okužba zgornjih dihal.
English: Magyarország GlaxoSmithKline Kft. Tel.: + 36 1 225 5300
Slovenian: GlaxoSmithKline Kft. Tel.: + 36 1 225 5300
English: If you accidentally use too much of this medicine, contact your doctor or pharmacist for advice immediately as you may need medical attention.
Slovenian: Če ste uporabili večji odmerek zdravila Incruse Ellipta, kot bi smeli Če pomotoma uporabite preveč tega zdravila, se za nasvet nemudoma obrnite na svojega zdravnika ali farmacevta, ker boste morda potrebovali zdravniško pomoč.
English: Sími: + 354 535 7000
Slovenian: Vistor hf. Sími: + 354 535 7000
English: Following intravenous administration to healthy subjects, the mean volume of distribution was 86 litres.
Slovenian: Porazdelitev Povprečni volumen porazdelitve po intravenski uporabi je bil pri zdravih preiskovancih 86 litrov.
English: There is no relevant use of Incruse Ellipta in the paediatric population (under 18 years of age) in the indication for COPD.
Slovenian: V pediatrični populaciji (mlajši od 18 let) zdravilo Incruse Ellipta nima relevantne uporabe za indikacijo KOPB.
English: What Incruse Ellipta is and what it is used for 2.
Slovenian: Kaj je zdravilo Incruse Ellipta in za kaj ga uporabljamo 2.
English: Incruse Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing.
Slovenian: Zdravila Incruse Ellipta se ne sme uporabljati za ublažitev nenadnega napada težkega ali piskajočega dihanja.
English: Eye problems during treatment with Incruse Ellipta If you get eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes during treatment with Incruse Ellipta:
Slovenian: Če se vam med zdravljenjem z zdravilom Incruse Ellipta pojavijo bolečine ali nelagodje v očesu, prehodna zamegljenost vida, videnje odsevov okrog stvari ali obarvane slike skupaj s pordelimi očmi:
English: In the 12-week study, Incruse Ellipta statistically significantly reduced the use of rescue medication with salbutamol compared with placebo (on average a reduction of 0.7 puffs per day over Weeks 1-12, p=0.025) and demonstrated a higher percentage of days when no rescue medication was needed (on average 46.3%) compared with placebo (on average 35.2%; no formal statistical analysis was performed on this endpoint).
Slovenian: Uporaba rešilnega zdravila V 12-tedenski študiji je zdravilo Incruse Ellipta statistično značilno zmanjšalo uporabo rešilnega zdravila s salbutamolom v primerjavi s placebom (povprečno zmanjšanje 0,7 vdiha na dan v obdobju od 1. do 12. tedna, p = 0,025) in je doseglo večji odstotek dni brez potrebe po rešilnem zdravilu (povprečno 46,3 %) kot placebo (povprečno 35,2 %; formalne statistične analize tega opazovanega dogodka niso izvedli).
English: Slovenská republika GlaxoSmithKline Slovakia s. r. o. Tel: + 421 (0)2 48 26 11 11 recepcia.sk@gsk.com
Slovenian: GlaxoSmithKline Slovakia s. r. o. Tel: + 421 (0)2 48 26 11 11 recepcia.sk@gsk.com
English: Multipack: 90 (3 packs of 30) doses
Slovenian: Skupno pakiranje: 90 (3 inhalatorji po 30) odmerkov
English: No dose adjustment is required in patients with mild or moderate hepatic impairment.
Slovenian: Bolnikom z blago ali zmerno okvaro jeter odmerka ni treba prilagoditi.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Incruse Ellipta in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use).
Slovenian: Ellipta za vse podskupine pediatrične populacije pri KOPB (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: The active substance is present as a white powder in a blister inside the inhaler.
Slovenian: Učinkovina je bel prašek v pretisnem traku v notranjosti inhalatorja.
English: Use Incruse Ellipta regularly
Slovenian: Zdravilo Incruse Ellipta uporabljajte redno
English: To use Incruse Ellipta, you breathe it into your lungs through your mouth using the Ellipta inhaler.
Slovenian: Zdravilo Incruse Ellipta uporabite tako, da ga s pomočjo inhalatorja Ellipta skozi usta vdihnete v pljuča.
English: If you forget to use Incruse Ellipta
Slovenian: Če ste pozabili uporabiti zdravilo Incruse Ellipta
English: Other medicines and Incruse Ellipta
Slovenian: Druga zdravila in zdravilo Incruse Ellipta